US2013144038A1PendingUtilityA1
CRYSTAL STRUCTURE OF A MarR FAMILY POLYPEPTIDE
Individually held — no corporate assignee on recordPriority: Jul 13, 2001Filed: May 15, 2012Published: Jun 6, 2013
Est. expiryJul 13, 2021(expired)· nominal 20-yr term from priority
C07K 2299/00C07K 14/245G01N 23/20
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The crystal structure of the product, crystals of the MarR protein, a regulator of multiple antibiotic resistance in Escherichia coli, and methods of crystallization of the MarR protein are described.
Claims
exact text as granted — not AI-modified1 . A crystallized MarR family polypeptide, wherein said crystallized MarR family polypeptide is crystallized under appropriate conditions such that the three dimensional structure of said MarR family polypeptide can be determined.
2 . The crystallized MarR family polypeptide of claim 1 , wherein the crystallized MarR family polypeptide is a structural homolog of crystallized MarR.
3 . The crystallized MarR family polypeptide of claim 1 , wherein said MarR family polypeptide is selected from the group consisting of MarR, SlyA, EmrR (MprA), PapX, PrsX, HpcR, Ec17kD of Escherichia coli; MarR, SlyA, EmrR of Salmonella typhimurium; MexR of Pseudomonas aeruginosa; PecS of Erwinia chrysanthemi; BadR of Rhodopseudomonas palustris; OrfE of Burkholderia pseudomallei; YdcH, YhbI, YkmA, YkoM, Orf7, YfiV, YetL, YdgJ, YwoH, YwaE, YwhA, Hpr, YybA, YxaD, YsmB, YusO, YpoP, YkvE of Bacillus subtilus;: Orf7 of Bacillus firmus;: Orf145, Orf141 of Staphylococcus sciuri;: CinR of Butyrivibrio fibrisolvens;: Orf158 of Sphingomonas aromaticivorans;: NhhD of Rhodococcus rhodochrous; Orf1 of Streptomyces peucetius;: 14.7 kD, Rv1404, Rv0737, Rv0042c, Yz08 (15.6 kD) of Mycobacterium tuberculosis; Yz08 (15.6 kD) of Mycobacterium leprae;: MTH313 of Methanobacterium thermoautotrophicum; Lrs14 of Sulfolobus solfataricus; CinR of Archaeoglobus fulgidus; PetP of Rhodobacter capsulatus; and SlyA (E293909) of Sinorhizobium meliloti.
4 . The crystallized MarR family polypeptide of claim 1 , wherein said MarR family polypeptide is MarR.
5 . The crystallized MarR family polypeptide of claim 4 , wherein the peptide sequence of MarR comprises the amino acid sequence shown in SEQ ID NO:2.
6 . The crystallized MarR family polypeptide of claim 4 , wherein said three dimensional structure has the space group of I4 1 22.
7 . The crystallized MarR family polypeptide of claim 1 , wherein said appropriate conditions include the presence of a MarR family polypeptide modulator.
8 . The crystallized MarR family polypeptide of claim 7 , wherein said MarR family polypeptide inhibitor is salicylate.
9 . The crystallized MarR family polypeptide of claim 1 , wherein said three dimensional structure is determined to a resolution of 5 Å or better.
10 .- 12 . (canceled)
13 . The crystallized MarR family polypeptide of claim 4 , wherein said crystallized MarR family polypeptide has a structure defined by the atomic coordinates given in FIG. 7 or FIG. 8 .
14 . (canceled)
15 . The crystallized MarR family polypeptide of claim 1 , wherein said MarR family polypeptide has a winged-helix structure.
16 . A crystallized MarR family polypeptide defined by the atomic coordinates given in FIG. 7 or FIG. 8 .
17 . (canceled)
18 . A method for determining the three dimensional structure of MarR family polypeptide, comprising
crystallizing the MarR family polypeptide under appropriate conditions such that crystals are formed; and analyzing the crystallized MarR family polypeptide, such that the three dimensional structure of the MarR family polypeptide is determined.
19 . The method of claim 18 , wherein said crystallized MarR family polypeptide is analyzed by x-ray diffraction techniques.
20 . The method of claim 18 , wherein said MarR family polypeptide is MarR.
21 . The method of claim 20 , wherein MarR comprises the amino acid sequence set forth in SEQ ID NO:2.
22 . The method of claim 18 , wherein said appropriate conditions comprise the presence of a MarR family polypeptide modulator.
23 . The method of claim 22 , wherein said MarR family polypeptide modulator is salicylate.
24 . The method of claim 18 , wherein said three dimensional structure is determined to a resolution of 5 Å or better.
25 .- 27 . (canceled)
28 . The method of claim 18 , wherein said MarR family polypeptide is selected from the group consisting of: MarR, SlyA, EmrR (MprA), PapX, PrsX, HpcR, Ec17kD of Escherichia coli; MarR, SlyA, EmrR of Salmonella typhimurium; MexR of Pseudomonas aeruginosa; PecS of Erwinia chrysanthemi; BadR of Rhodopseudomonas palustris; OrfE of Burkholderia pseudomallei; YdcH, YhbI, YkmA, YkoM, Orf7, YfiV, YetL, YdgJ, YwoH, YwaE, YwhA, Hpr, YybA, YxaD, YsmB, YusO, YpoP, YkvE of Bacillus subtilus;: Orf7 of Bacillus firmus;: Orf145, Orf141 of Staphylococcus sciuri;: CinR of Butyrivibrio fibrisolvens;: Orf158 of Sphingomonas aromaticivorans;: NhhD of Rhodococcus rhodochrous; Orf1 of Streptomyces peucetius;: 14.7 kD, Ry1404, Rv0737, Rv0042c, Yz08 (15.6 kD) of Mycobacterium tuberculosis; Yz08 (15.6 kD) of Mycobacterium leprae;: MTH313 of Methanobacterium thermoautotrophicum; Lrs14 of Sulfolobus solfataricus; CinR of Archaeoglobus fulgidus; PetP of Rhodobacter capsulatus; and SlyA (E293909) of Sinorhizobium meliloti.
29 . (canceled)Join the waitlist — get patent alerts
Track US2013144038A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.